policy evaluation

Health policy researchers often have questions about the effects of a policy implemented at some cluster-level unit, e.g., states, …

Background: State medical cannabis laws may lead patients with chronic noncancer pain to substitute cannabis in place of prescription …

A talk at SER 2023 in an invited symposium titled “Specifying and emulating target trials to estimate causal effects of complex exposures” organized by Ellen Caniglia.

A contributed presentation at JSM 2022. Part of a session on “Statistical Methods in Policy Evaluation: From COVID-19 to Medical Cannabis–Related Policy”.

A talk for the Research in Progress seminar series from the Johns Hopkins ALACRITY Center for Health and Longeivty in Mental Illness. I provide an overview of difference-in-differences (DiD), highlight a challenge (and solution) that arises when using individual-level data in DiD analyses, and offer guidance on when and how individual-level data is useful.

Policy implementation is a key component of scaling effective chronic disease prevention and management interventions. Policy can …

A contributed presentation at JSM 2022. Part of a session on “Statistical Methods in Policy Evaluation: From COVID-19 to Medical Cannabis–Related Policy”.

A poster at AcademyHealth Annual Research Meeting 2022. I describe a simulation study investigating performance of difference-in-differences methods using hierarchical data for state-level health policy evaluation.

A talk at the 2022 American Causal Inference Conference offering advice on communicating cutting-edge methods for an applied audience, drawing on experience with using the augmented synthetic control method in a paper published in the Annals of Internal Medicine. Part of a session on methodological innovations for challenges in health policy and clinical care.

Background: There is concern that state laws to curb opioid prescribing may adversely affect patients with chronic noncancer pain, but …